Lupin Receives Tentative FDA Approval for Generic Siponimod Multiple Sclerosis Treatment
核心洞察
Lupin Limited has received tentative FDA approval for its generic version of Siponimod tablets in 0.25 mg, 1 mg, and 2 mg strengths for treating relapsing forms of multiple sclerosis (搜索).
The generic formulation is bioequivalent to Novartis' Mayzent and will be manufactured at Lupin's Pithampur facility in India.
The reference drug Mayzent had estimated annual U.S. sales of $195 million according to IQVIA data from October 2025.
Global pharmaceutical company Lupin Limited announced it has received tentative approval from the United States Food and Drug Administration (U.S. FDA (搜索)) for its Abbreviated New Drug Application for Siponimod Tablets in 0.25 mg, 1 mg and 2 mg strengths. The generic formulation represents a significant entry into the multiple sclerosis (搜索) treatment market, targeting a condition that affects the brain and spinal cord through immune system attacks.
Manufacturing and Bioequivalence
The approved Siponimod tablets will be manufactured at Lupin's Pithampur facility in India. According to the company, the generic formulation demonstrates bioequivalence to Mayzent Tablets (0.25 mg, 1 mg and 2 mg) manufactured by Novartis Pharmaceuticals Corporation, ensuring therapeutic equivalence to the reference drug.
Therapeutic Indication and Market Impact
The FDA approval covers treatment of relapsing forms of multiple sclerosis (搜索), including clinically isolated syndrome (搜索), relapsing remitting disease (搜索), and active secondary progressive disease (搜索) in adults. Multiple sclerosis presents with varied symptoms depending on the location and severity of nerve fiber damage, commonly including vision problems, fatigue, mobility issues, balance difficulties, and numbness or weakness in extremities.
The market potential for this generic entry is substantial, with Siponimod tablets (reference drug Mayzent) recording estimated annual U.S. sales of $195 million according to IQVIA MAT data from October 2025.
Disease Background
Multiple sclerosis (搜索) occurs when the immune system attacks the brain and spinal cord, though the exact causes remain unknown. Family history may increase disease risk. Symptoms can be intermittent or persistent, with manifestations varying significantly between patients based on the specific areas of neurological damage.
Company Profile
Mumbai-headquartered Lupin Limited operates as a global pharmaceutical company with products distributed across over 100 markets. The company maintains a diverse portfolio spanning branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin holds strong market positions in India and the United States across multiple therapeutic areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health, supported by 15 manufacturing sites and 7 research centers worldwide.